Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

Haematologica

Volumn 96, Issue 7, 2011, Pages 963-971

  Möllgård, Lars ^a   Saft, Leonie ^a   Treppendahl, Marianne Bach ^b   Dybedal, Ingunn ^c   Norgaard, Jan Maxwell ^d   Astermark, Jan ^e   Ejerblad, Elisabeth ^f   Garelius, Hege ^g   Dufva, Inge Høgh ^h   Jansson, Monika ^a   Jädersten, Martin ^a   Kjeldsen, Lars ^b   Linder, Olle ⁱ   Nilsson, Lars ^e   Vestergaard, Hanne ^j   Porwit, Anna ^a   Grønbaek, Kirsten ^b   Lindberg, Eva Hellström ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁱ ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^j LILLEBAELT HOSPITAL   (Denmark)

more..

Author keywords

Acute myeloid leukemia; Lenalidomide; Myelodysplastic syndrome; P53 mutation

Indexed keywords

LENALIDOMIDE; PROTEIN P21; PROTEIN P53; WT1 PROTEIN;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTHRITIS; ARTICLE; BRAIN HEMORRHAGE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM HEMORRHAGE; CHROMOSOME 5; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; INFECTION; KARYOTYPE; LEUKEMIA RELAPSE; MALE; MONOSOMY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SYNCOPE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TP53 GENE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; ONCOGENE PROTEIN P21(RAS); THALIDOMIDE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; WT1 PROTEINS;

EID: 79959950825     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.039669     Document Type: Article

References (32)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
2. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, et al. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma. 2010;51(1):73-8.
3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88.
4. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood. 2010;116(3):354-65.
5. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-95.
6. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312-20.
7. Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica. 2004;89(8):998-1008.
8. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355(14):1456-65.
9. Ades L, Boehrer S, Prebet T, Beyne-Rauzy O, Legros L, Ravoet C, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 2009;113(17):3947-52.
10. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. 2010;28(33):4919-25.
11. Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, et al. A phase II study of high dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 2011;117(6):1828-33.
12. Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci USA. 2007;104(27):11406-11.
13. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA. 2009;206(31):12974-9.
14. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapyrelated myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001; 19(5):1405-13.
15. Merlat A, Lai JL, Sterkers Y, Demory JL, Bauters F, Preudhomme C, et al. Therapyrelated myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia. 1999;13(2):250-7.
16. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008; 22(2):240-8.
17. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69(18):7347-56.
18. Jadersten M, Saft L, Pellagatti A, Gohring G, Wainscoat JS, Boultwood J, et al. Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica. 2009;94 (12):1762-6.
19. Amato RJ, Harris P, Dalton M, Khan M, Alter R, Zhai Q, et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol (Meeting Abstracts). 2007;25(18 suppl):5026.
20. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-57.
21. Jadersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26 (21):3607-13.
22. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon. 2008.
23. Iwasaki T, Murakami M, Sugisaki C, Sobue S, Ohashi H, Asano H, et al. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia. Pathol Int. 2008;58(6):353-60.
24. Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol. 2003;21(10):1988-95.
25. Tamura H, Dan K, Yokose N, Iwakiri R, Ohta M, Sakamaki H, et al. Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. Leuk Res. 2010;34(8):986-90.
26. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J. Singlestep DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat. 1997;9(4):348-55.
27. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-9.
28. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-25.
29. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400-14.
30. Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 1993;7(10):855-65.
31. Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Hedlund A, et al. TP53 mutations in low-risk 1 myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2010;29(15):1971-9.
32. Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Latham D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol. 2010;28(13):2253-8.